Alpelisib and radiotherapy treatment enhances Alisertib-mediated cervical cancer tumor killing
Journal: Am J Cancer Res. (2021)
Institution: Griffith University
Research Areas: Cancer research
Cell Lines: HeLa (Cervical cancer cell line)
Summary: Human papillomavirus (HPV) is the main causative agent in cervical cancers. High-risk HPV cancers, including cervical cancer, are driven by major HPV oncogene E6 and E7, which promote uncontrolled cell growth and genomic instability. Authors tested if MLN8237 (Alisertib), an oral, selective inhibitor of AURKs, can improve tumor response when combined with either radiotherapy (RT) treatment or with a PI3K inhibitor BYL719 (Alpelisib). Results indicated that both RT and Alpelisib significantly improved Alisertib-mediated tumor killing, and the promising achieved results warrant further development of these combinations and potentially translating them to the clinics.